Eli Lilly and Company reported first-quarter earnings of $2.62 per share, exceeding the Zacks Consensus Estimate of $2.32. The company posted revenues of $7.8 billion, up 15% year-over-year, boosted by $1.47 billion from COVID-19 therapies. In response to this strong performance, Eli Lilly increased its full-year revenue guidance to between $28.8 billion and $29.3 billion. Additionally, promising results from its experimental weight-loss drug, tirzepatide, further elevate hopes for future growth.
“Eli Lilly and Company · earned · $2.62 per share · on an adjusted basis”
“Eli Lilly and Company · posted · revenue · $7.8 billion”
“Eli Lilly · is more expensive than · Johnson & Johnson”
“Eli Lilly · is trading at · 31 forward P/E”
“Eli Lilly and Company · earned · adjusted earnings · $2.62 per share”
“Eli Lilly and Company · posted · revenue · $7.8 billion”
“Lilly · announced · first-quarter results · better than expected”
“Lilly · beat · estimates for sales · yes”
“Lilly · beat · estimates for earnings · yes”
“Lilly · raised · revenue expectations for 2022 · due to higher COVID-19 antibody revenues”
“Eli Lilly · announced · tirzepatide · showed superior weight loss”
“Eli Lilly And Company · accounts for about · 0.58% of total assets”
